DRUG

Bright Minds BiosciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$110.00

Analysis reference price unavailable

Analysis 2026-08-22 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$68.00

Analysis reference price unavailable

Analysis 2026-08-22 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$45.00

Analysis reference price unavailable

Analysis 2026-08-22 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-22

AI commentary

Coverage is low and the packet contains no usable social aggregate or recent company-specific news flow. The primary clinical readout is constructive, and the company has stated forward plans for registrational preparation and long-term data, but those plans lack dated milestones or confirmation of progress; the setup remains a low-conviction monitoring case.

RankAlpha Sentiment Codex - 2026-08-22

Open full AI memo

Evidence flagged

Forward visibility is limited, so this memo should be read as a lower-conviction monitoring view rather than a catalyst-driven call.; no forward-looking company-specific catalyst is supported by primary-source evidence

Impact

tentative

Confidence

AI events

2026-01-06eventPositive BMB-101 Phase 2 topline readoutMedium impact

The company reported a 73.1% median reduction in absence seizures and a 63.3% median reduction in major motor seizures, with favorable tolerability and no new safety signals [#IR-2026-01-06]. The readout is already public and likely substantially reflected in the share price.

2027-08-22catalystBMB-101 registrational preparation and additional dataHigh impact

Bright Minds said it initiated preparations for global registrational trials in absence seizures and DEE and expected to present additional long-term outcome data throughout 2026. No specific milestone date or execution update was disclosed [#SEC-6K-2026-01-06].

2027-08-22catalystExpansion of PWS and BMB-105 programsHigh impact

The company has described preparatory work for a BMB-101 Prader-Willi Syndrome study and expected BMB-105 Phase 1 development, supported by proceeds from its January financing [#SEC-6K-2026-01-08][#SEC-6K-2026-02-12]. Timing remains undisclosed.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-22 • Updated nightlySource: Internal modelMethodology